Back to search results

Pilot Study of Fisetin for Age-Related Lung Function Decline

This study is testing whether a natural compound called fisetin can help improve lung function in older adults. You might be able to join if you are 60 or older and are physically able to participate. The study is looking for 40 participants, including those with a history of smoking and those who have never smoked. Participants will receive either fisetin or a placebo (an inactive substance) for a short period. Researchers will measure your lung function (like how much air you can breathe out) at the beginning and after two weeks to see if fisetin has an effect. The study status is currently unclear, meaning it might not be actively recruiting yet.

Study design
This is a Phase II, randomized, double-blind, placebo-controlled pilot study involving 40 participants. You will be randomly assigned to receive either fisetin or a placebo, and neither you nor the researchers will know which you are receiving.
What's involved
You will take capsules for two days, then again for two more days a week later. Over a two-week period, you will have clinical evaluations, lung function tests, exercise tests, heart tests (electrocardiography), and give blood and urine samples.
Compensation
Not stated in the trial record.
Follow-up
Your lung function will be measured at the beginning of the study and again on Day 14, which is two weeks after the study starts.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07676435

Ongoing Lung Decline With Age Intensified Response

Recruiting
PHASE2Ages 60+InterventionalTreatment
Cedars-Sinai Medical Center
~40 participants
Updated 2026-07-01 on ClinicalTrials.gov
What's tested:FisetinPlacebo

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Forced Vital Capacity (FVC)
Measured over Baseline and Day 14
+2 more outcomes measured

Conditions

Age-Related Lung Function Decline

Explore related trials

Age-Related Lung Function DeclineAgingCellular SenescenceSmoking-Related Lung Function Decline

NCT07676435

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Cedars-Sinai Medical Center

    Los Angeles, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Samuel Cohen, MD
[email protected]
310-423-1725
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adults aged 60 years and older who are physically capable of participating in study procedures;
Willing to be randomized to fisetin or placebo; weight stable within the previous 2 months (\<5-pound change);
No blood donation within 2 months before screening; absence of unstable chronic disease;
Willing to maintain baseline activity level throughout the study;
Body mass index \<30 kg/m²;
Either a history of at least 10 pack-years of cigarette smoking or never-smoking status.

Exclusion

Electrocardiogram (ECG) abnormalities, including prolonged QTc.
Use of fisetin, other flavonoid supplements, or known senolytic compounds within 6 months prior to screening.
Resting systolic blood pressure \>160 mmHg or diastolic blood pressure \>110 mmHg.
Known allergy or hypersensitivity to fisetin or any component of the study product.
Active malignancy, except non-melanoma skin cancer.
Clinically significant hepatic, renal, cardiovascular, endocrine, immunologic, metabolic, or other uncontrolled medical conditions that, in the opinion of the investigator, would interfere with study participation or interpretation of results.
Clinically significant laboratory abnormalities, including severe anemia, leukopenia, thrombocytopenia, uncontrolled diabetes, advanced kidney disease, significant liver dysfunction, or evidence of systemic inflammation.
Human immunodeficiency virus (HIV) infection, active hepatitis B or hepatitis C infection, or invasive fungal infection.
History of diverticulitis or diverticulosis with gastrointestinal bleeding.
Current use of systemic corticosteroids.
Current use of warfarin.
Current use of medications with significant interaction potential with fisetin, including selected CYP450 or transporter substrates, inhibitors, or inducers, unless such medications can be safely withheld according to protocol requirements.
Recent medication, supplement, or lifestyle changes that may affect study outcomes, in the opinion of the investigator.
Inability to perform required study procedures, including pulmonary function testing, exercise testing, or other protocol assessments.
Unwillingness or inability to provide informed consent.
Pregnancy or breastfeeding.
Any other condition that, in the opinion of the investigator, would make participation unsafe or compromise study integrity.

What this trial measures

  • Forced Vital Capacity (FVC)Baseline and Day 14

    Forced vital capacity measured by spirometry to assess lung function following treatment with fisetin versus placebo.

  • Forced Expiratory Volume in 1 Second (FEV1)Baseline and Day 14

    Forced expiratory volume in one second measured by spirometry following treatment with fisetin versus placebo.

  • FEV1/FVC RatioBaseline and Day 14

    Ratio of FEV1 to FVC measured by spirometry following treatment with fisetin versus placebo.